Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piero L Olliaro

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Current Opinion in Infectious Diseases|September 28, 2010
Drug combinations for visceral leishmaniasisPiero L Olliaro
The Lancet. Respiratory Medicine|May 8, 2021
An integrated understanding of long-term sequelae after acute COVID-19Piero L Olliaro
The Lancet. Infectious Diseases|January 6, 2018
Initiation and publication time-lags of treatment trials for Ebola virus diseasePiero L Olliaro
Therapeutics and Clinical Risk Management|May 14, 2008
Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk managementShyam Sundar, Piero L Olliaro
Plos Medicine|July 13, 2019
Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectivenessPiero L Olliaro, Michel Vaillant
Plos Neglected Tropical Diseases|November 21, 2014
Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trialsJulien Zwang, Piero L Olliaro
The Lancet. Respiratory Medicine|July 28, 2020
The time to do serosurveys for COVID-19 is nowRosanna W Peeling, Piero L Olliaro
Frontiers in Public Health|January 8, 2024
Addressing stigma in infectious disease outbreaks: a crucial step in pandemic preparednessAmy Paterson, Piero L Olliaro, Amanda Rojek
The Journal of Experimental Biology|September 25, 2003
Antimalarial compounds: from bench to bedsidePiero L Olliaro, Walter R J Taylor
The Lancet. Infectious Diseases|December 16, 2018
Epidemic preparedness: why is there a need to accelerate the development of diagnostics?Rosanna W Peeling, Maurine Murtagh, Piero L Olliaro
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Current Opinion in Infectious Diseases|September 28, 2010
Drug combinations for visceral leishmaniasisPiero L Olliaro
The Lancet. Respiratory Medicine|May 8, 2021
An integrated understanding of long-term sequelae after acute COVID-19Piero L Olliaro
The Lancet. Infectious Diseases|January 6, 2018
Initiation and publication time-lags of treatment trials for Ebola virus diseasePiero L Olliaro
Therapeutics and Clinical Risk Management|May 14, 2008
Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk managementShyam Sundar, Piero L Olliaro
Plos Medicine|July 13, 2019
Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectivenessPiero L Olliaro, Michel Vaillant
Plos Neglected Tropical Diseases|November 21, 2014
Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trialsJulien Zwang, Piero L Olliaro
The Lancet. Respiratory Medicine|July 28, 2020
The time to do serosurveys for COVID-19 is nowRosanna W Peeling, Piero L Olliaro
Frontiers in Public Health|January 8, 2024
Addressing stigma in infectious disease outbreaks: a crucial step in pandemic preparednessAmy Paterson, Piero L Olliaro, Amanda Rojek
The Journal of Experimental Biology|September 25, 2003
Antimalarial compounds: from bench to bedsidePiero L Olliaro, Walter R J Taylor
The Lancet. Infectious Diseases|December 16, 2018
Epidemic preparedness: why is there a need to accelerate the development of diagnostics?Rosanna W Peeling, Maurine Murtagh, Piero L Olliaro
Pageof 11